Digestive Disease Week 2020 (DDW 2020)

Vonoprazan tops lansoprazole in reducing erosive oesophagitis recurrence in Asians

Roshini Claire Anthony, 20200619140003

A once-daily maintenance dose of vonoprazan 10 mg or 20 mg may be a suitable substitute to lansoprazole in reducing the risk of erosive oesophagitis (EE) recurrence, according to a phase III noninferiority study presented at DDW 2020.

Too much or too little sleep triggers constipation

Elvira Manzano, 20200617153000

Too much or too little sleep triggers constipation in a study of nearly 15,000 adults.

Regular aspirin use may reduce GI cancer risk

Roshini Claire Anthony, 20200616140002

Regular use of aspirin may reduce the risk of gastrointestinal cancers, according to two studies presented at DDW 2020.

Plecanatide favourable for older individuals with CIC, IBS-C

Audrey Abella, 20200616100000

The guanylate cyclase-C receptor agonist plecanatide is effective and well-tolerated by older individuals (≥65 years) with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), results of a post hoc analysis presented at DDW 2020 has shown.

Rifaximin effective in treatment unresponsive IBS-D

Roshini Claire Anthony, 20200615150003

Patients with irritable bowel syndrome with diarrhoea (IBS-D) who have not responded to other medications may benefit from rifaximin, post hoc analyses of the TARGET 3* trial showed.

SC vedolizumab improves outcomes in patients with Crohn’s disease

Audrey Abella, 20200612100000

Maintenance therapy with a new subcutaneous (SC) formulation of the monoclonal antibody vedolizumab led to improvements in patient-reported outcomes (PROs) in patients with moderate-to-severe active Crohn’s disease (CD) compared with placebo, interim results of the phase III VISIBLE 2 study has shown.

Budesonide oral suspension improves endoscopic outcomes in eosinophilic oesophagitis

Audrey Abella, 20200608100000

Budesonide oral suspension (BOS), a liquid formulation of a topical corticosteroid, improved endoscopic outcomes in patients with eosinophilic oesophagitis (EoE), a phase III trial has shown.